TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
N4 Pharma ( (GB:N4P) ) just unveiled an announcement.
N4 Pharma has published a new article highlighting the potential of its Nuvec® platform in RNA therapeutics, emphasizing the delivery challenges and how Nuvec® is positioned to address them. This development is part of N4 Pharma’s strategy to build preclinical data and progress towards first-in-human clinical trials, which could lead to significant licensing opportunities and strengthen its position in the biotech industry.
More about N4 Pharma
N4 Pharma is a pre-clinical biotech company based in the UK, focusing on developing Nuvec®, a proprietary gene delivery system designed to enhance advanced therapies for cancer and other diseases. The company aims to leverage Nuvec®’s capabilities in RNA therapeutics, which include delivering multiple RNA therapies in a single particle, ease of manufacturing, and protection of the RNA payload for oral delivery, to support significant licensing deals with commercial partners.
Average Trading Volume: 1,206,564
Technical Sentiment Signal: Sell
Current Market Cap: £6.47M
Find detailed analytics on N4P stock on TipRanks’ Stock Analysis page.